MabThera/Rituxan

Ocrevus surge keeps Roche smiling in Q3

As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in Europe. ... 9% overall thanks to gains in the US, where it is sold as Rituxan, as well as international markets,

Encouraging data for Roche flu drug ahead of FDA decision

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

ABPI hits out at ‘punitive’ UK medicines cost controls

set a target of £300m in savings from biosimilars in the next three years – led by cheaper versions of drugs such as Herceptin, MabThera and Humira – but Warwick Smith says the

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Roche has seen revenues from blockbuster MabThera/Rituxan slashed in half in Europe thanks to growing biosimilar competition in the second quarter.

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates. Celgene has new phase III data that could add yet another string to blockbuster Revlimid’s bow – as a treatment ... a significant increase in progression-free survival (PFS) compared

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]